RENAL AND UROLOGICAL PROBLEMS: Edited by Fred SaadThe evolving options in metastatic castration-sensitive prostate cancerHamilou, ZinebAuthor Information Centre Hospitalier de l’Université de Montréal, Montréal, Canada Correspondence to Zineb Hamilou, MD, Centre Hospitalier de l’Université de Montréal, Montréal, Canada. Tel: +1 514 890 8000 x20696; e-mail: [email protected] Current Opinion in Supportive and Palliative Care: September 2020 - Volume 14 - Issue 3 - p 270-275 doi: 10.1097/SPC.0000000000000507 Buy Metrics Abstract Purpose of review Leading trials CHAARTED, STAMPEDE, GETUG-AFU15 and LATITUDE established docetaxel and abiraterone acetate addition to androgen deprivation therapy (ADT) as a treatment guideline for patients with metastatic castration-sensitive prostate cancer. Recent findings Two recent combinations, enzalutamide with ADT and apalutamide with ADT were tested in metastatic castration-sensitive prostate cancer in three randomized controlled trials. Both combinations provided survival gain, expanding our options of treatment. Moreover, additional evidence behind radiotherapy for the primary tumor in metastatic prostate cancer is emerging. Summary In this updated article, we review the data of these trials and highlight the distinctions between these therapies, in order to better personalize the care for patients with metastatic prostate cancer. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.